BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal

BridgeBio Pharma (NASDAQ:BBIO) has lost ~67.9% in the pre-market after the company said that its ongoing Phase 3 study for acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint at Month 12.